Crescendo Bioscience Closes on $56M
Crescendo Bioscience, a molecular diagnostics company developing quantitative biomarker tests for rheumatoid arthritis and other diseases, has raised a total of $56 million in fresh capital. The company inked $31 million in Series C financing, and sealed a strategic investment agreement with Myriad Genetics for $25 million. Venture investors include Aeris Capital, Mohr Davidow Ventures and Kleiner Perkins Caufield & Byers. The $25 million investment by Myriad Genetics is structured as long-term debt with a three-year option to acquire Crescendo Bioscience.
9 September 2011•3 mins read
